Singer Releases Song About MS Recovery After Receiving Stem Cell Therapy

Singer Kristen King began to experience fatigue, muscle weakness and later paralysis in some parts of the body in 2013, and it came as a shock when she was diagnosed with multiple sclerosis (MS). After struggling to deal with the unfortunate news and her new reality, the singer has now launched a new song entitled “Impervious” about her battle with the disease, which led her to undergo a stem cell treatment.

The new single written and released by Kristen King portrays her emotional journey and how the chronic condition impacted her life. The singer pictures the strength needed to face MS, as well as her reluctance to succumb to the disease. Part of her effort to overcome MS is asserting the belief that she is “impervious” to it — the word she used to title the song. After undergoing stem cell therapy, Kristen now has a newfound energy that she wants to use it to improve her quality of life as well as help others.

After exploring therapeutic options, stem cell treatment seemed to Kristen to be her best option, when her entire life was shaken by the diagnosis that threatened to put a thriving performer into a disabled body. Kristen feared the decline in her quality of life, as well as the burden that life-long dependency would mean for her family. Similar to other MS patients, she started searching for information on the internet, determined to look for other options and hope.

That was when Kristen King started reading about the novel method to treat MS, stem cell therapy. After carefully considering the opinions of other patients, as well as medical and scientific professionals, the singer decided to look into U.S. based company StemGenex, which is specialized in stem cell therapy, explaining in a press release that there “had to be something to this stem cell thing.”

After receiving the stem cell treatment in November 2014, the singer saw her MS symptoms improve, and was able to release her new single and recover part of her old life back. The therapy chosen by Kristen King at StemGenex consists of a customized treatment according to each patient’s symptoms that include multiple administration methods, including novel and cutting-edge techniques to make the stem cells transpose the blood-brain barrier and deliver it directly in the brain cells.

“There is a growing body of medical literature supporting the efficacy of stem cell therapy in multiple sclerosis,” stated the StemGenex’s lead investigator Jeremiah McDole, PhD. “Clinical studies have demonstrated a reduction in relapsing symptoms. However, much more exciting developments have taken place including recent work suggesting that progressive disease may be slowed or even halted by stem cell therapy — an achievement not documented with standard medications. We are excited about this ongoing work as well as our own studies.”

The stem cell therapy is expected to improve MS symptoms, such as brain fog, balance, fatigue, numbness or tingling of the extremities and vision problems, while additional localized injections are used to address other symptoms like spasticity and foot drop and specialized bladder treatment to decrease incontinence. StemGenex is one of the few companies in the United States to offer adult adipose stem cell therapy to patients who suffer from Parkinson’s disease, Alzheimer’s disease, COPD, auto-immune diseases and other conditions, in addition to MS.

Last June, the company announced it was initiating a clinical trial focused on the regenerative potential of MS patients’ autologous stem cells derived from their own stromal vascular fraction. The study, which includes about 100 MS patients and is projected to end by May 2017, was designed to investigate a new, unique stem cell therapy that is potentially more effective than current stem cell therapies.

Of course, Kristen’s story extolling the merits of stem cell therapy for the treatment of multiple sclerosis is not a completely unique one: stem cell therapy has become a popular and controversial topic in the MS community over the past few years. While companies such as StemGenex are working hard to accelerate the adoption of stem cell therapy for diseases such as MS, other factions within the medical community are still encouraging patients to tread carefully with stem cell treatment options, as there have been conflicting studies on its true efficacy in the long-term. However, given the rise in anecdotal evidence that stem cell treatments may be a viable option for some MS patients, stories such as Kristen’s are bound to spur on continued research and development in the near future.